Video of PowerPoints with Synchronized Audio (WMV video)

Available in two formats:
Digital Download - $17
CD-ROM - $23


EXAMINING THE VALUE OF NEUROPSYCHOLOGICAL TESTING IN THE ERA OF BIOMARKERS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

Mark Bondi, PhD, ABPP-CN
Professor of Psychiatry, University of California San Diego, School of Medicine La Jolla, CA, USA Director, Neuropsychological Assessment Unit, Psychology Service, VA San Diego Healthcare System San Diego, CA, USA

With the recent publications of the NIA-Alzheimer's Association workgroups on revising the criteria for diagnosis of dementia due to Alzheimer's disease (AD; McKhann et al., 2011), mild cognitive impairment (MCI; Albert et al., 2011), and preclinical AD (Sperling et al., 2011), it is clear we are entering an era increasingly focused on the role of biomarkers in disease detection, diagnosis, and predicting clinical outcome. In this workshop we will review evidence of the relative value of genetic, imaging, and CSF markers in the early detection and diagnosis of AD. The workshop will also present how MCI is typically defined and examine its ramifications for diagnosis and clinical outcome. We will present evidence that neuropsychological assessment provides a central and non-interchangeable role in diagnosing AD and MCI, and that cognitive measures are among the best predictors of the initial symptomatic stages of an evolving dementia (i.e., prodromal AD). By the end of the workshop, participants will (1) be able to describe three classes of biomarkers for Alzheimer's disease, and (2) be aware of the relative value of biomarkers and neuropsychological assessment to diagnosis of AD and prediction of progression from MCI to AD.